The making of DNA

Enabling the genetic medicine revolution with our unique doggybone DNA (dbDNA™) technology.

How we make DNA
Platform Technology

doggybone DNA:
Powering the genetic medicine revolution

Our novel, synthetic DNA vector, doggybone DNA or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.

Doggybone DNA animation
Enzymatic DNA

DNA made using enzymes

We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.

Our platform technology
Rapid enzymatic DNA technology
Rapid

Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months

Scalable enzymatic DNA technology
Scalable

Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production

Mobile enzymatic DNA
Mobile

doggybone DNA technology is highly portable and amenable to technology transfer

Optimal enzymatic DNA vector
Optimal vector

doggybone DNA can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile

Addressing a broad market

Our versatile doggybone DNA (dbDNA) technology is being applied across the genetic medicine industry.

mRNA icon

mRNA

Find out more
Lentivirus

Lentivirus

Find out more
AAV icon

AAV

Find out more
Genome editing icon

Genome editing

Find out more
DNA vaccines icon

DNA vaccines

Find out more
Non viral gene therapy

Non-viral gene therapy

Find out more
Our Services

What can we do for you?

We offer a range of services to support development and commercialisation of the next generation of DNA products.

doggybone DNA for pre-clinical development
Pre-clinical services
  • Catalogue products
  • Molecular biology
  • Custom research grade
  • Toxicology materials
Find out more
enzymatic doggybone DNA GMP Supply
GMP supply
  • GMP dbDNA™ (critical starting materials)
  • GMP dbDNA™ (drug substance)
  • Commercial supply / on-site supply
Find out more
enzymatic DNA development services
Development Services
  • Analytical development
  • Scale up development
  • Formulation
  • Stability
Find out more
Regulatory Support for genetic medicine development
Regulatory support
  • Regulatory support
Find out more
Our facilities

Headquartered in Hampton

Take a tour of our stunning buildings and state-of-the-art DNA manufacturing facilities.

View our facilities
Our programs and partners

Work with us to develop the next generation of DNA products

We are working in collaboration with esteemed partners, to leverage doggybone DNA in areas where it may offer unique or improved therapies or devices.

Find out more
Find out more

Knowledge Centre

Clarivate podcast, Conversations in Healthcare titled, 'Lighting the touch paper for next generation nucleic acid therapies featuring Jonny Ohlson, Executive Chair & Founder at Touchlight
Jonny Ohlson

Jonny Ohlson

Clarivate Podcast – Lighting the touch paper for next generation nucleic acid therapies
Read Article
Supporting the clinical adoption of enzymatic DNA
Webinar – Supporting the Clinical Adoption of Enzymatic DNA in Advanced Therapy Manufacturing
Read Article
Nature Reviews Chemistry – DNA synthesis technologies to close the gene writing gap
Nature Reviews Chemistry – DNA synthesis technologies to close the gene writing gap
Read more
Enabling better genetic medicines with enzymatic DNA - doggybone DNA
Brochure – Touchlight doggybone DNA
Download
AAV Manufactureing, Overcoming challenges of plasmid DNA. On demand webinar.
Webinar – Overcoming the challenges of plasmid DNA in AAV manufacturing
Read Article
White paper on lentivirus manufacturing
Sarah Moore

Dr Sarah Moore

White Paper – The future of Industrial Scale Lentiviral Vector Manufacturing
Read Article
Knowledge centre

News

24 May 2023

Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK

Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.  Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton,...

18 April 2023

20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project

Enschede, The Netherlands, and Hampton, UK - April 18, 2023 – 20Med Therapeutics, a leader in non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company...

29 March 2023

Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing

Hampton, UK, 29 March 2023 – Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced that it has secured a grant from the Department for Science,...
All news
Contact us

We'd like to hear from you

For more information on how our doggybone DNA technology could help advance your project, please contact us.

Get in touch